



DETERMA^{Rx}TM + EGFR

Now Available!
DetermaRx and EGFR testing
from the same tissue sample

DetermaRxTM is a treatment stratification test to identify patients with stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.¹

Now paired from the same tissue sample

DetermaRx + EGFR is the complete molecular testing solution in early-stage NSCLC, guiding treatment selection and sequencing of targeted therapy (osimertinib) and adjuvant chemotherapy

Gaining clinically actionable results to manage your early-stage patients is easy

- Order DetermaRx for your patient with stage I or IIA non-squamous NSCLC undergoing surgical resection
- You may opt in for EGFR mutation analysis on the same tissue sample if you wish
- You will receive a consolidated report to enable informed chemotherapy and targeted therapy treatment decisions



Edgardo Santos, MD, FACP
Florida Precision Oncology

"The integration of testing for targeted therapy, including EGFR mutation status and chemotherapy selection by DetermaRx on the same sample, will enable oncologists to optimize and sequence treatment post-surgery. In my opinion, these two tests together close the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I would feel confident initiating chemotherapy, followed by targeted therapy for the EGFR-positive, DetermaRx high-risk patients I see in my practice."

Order now

We are committed to providing accessible, affordable testing for all.

Learn more at:

<https://oncocyte.com/determarx-how-to-order>

Please visit our webinar to see experts weigh in on treatment strategies for DetermaRx and EGFR results in early-stage NSCLC.

<https://tinyurl.com/DetermaRxWebinar>

REFERENCES 1. Woodard GA, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. *Clinical Lung Cancer* 19:58-64.